Skip to main content

Select Drug Profiles

Specialty Pharmaceuticals Update

David B. Nash, MD, MBA

Implications of the Employer Mandate Delay on the Healthcare Marketplace

Kip Piper, MA, FACHE, F. Randy Vogenberg, PhD, FASHP

Practice Management

Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases

Marie-Hélène Lafeuille, MA, Jonathan Gravel, MSc, Amanda Grittner, MA, Patrick Lefebvre, MA, Lorie A. Ellis, PhD, Scott McKenzie, MD

Stakeholder Perspective

“Roid Rage”

by Atheer A. Kaddis, PharmD

Original Research

Perspectives of Quality Care in Cancer Treatment: A Review of the Literature

Lisa M. Hess, PhD, Gerhardt Pohl, PhD

Stakeholder Perspective

Quality of Cancer Care: Emerging Definition and Measurements, but Reimbursement Lagging

by Craig K. Deligdish, MD

Original Research

Burden of Disease: The Psychosocial Impact of Rosacea on a Patient’s Quality of Life

Tu T. Huynh, PhD

Stakeholder Perspective

The Psychosocial Impact of Skin Disorders: Time for a Closer Look?

by Matthew Mitchell, PharmD, MBA, FAMCP

ASCO President Highlights Bridges to Conquer Cancer

Off-Label Drug Use in Oncology Accounts for 18% of Spending

Caroline Helwick

Melanoma, Oncology

Immunotherapies Take Center Stage in Melanoma

Cancer Drug Pipeline Is Bustling

Caroline Helwick, Wayne Kuznar

Mekinist and Dabrafenib Approved for Advanced Melanoma with BRAF Mutations

Page 175 of 244
Results 1741 - 1750 of 2438